Gaining momentum: New options and opportunities for the treatment of advanced melanoma

Cancer Treatment Reviews

Volumn 41, Issue 8, 2015, Pages 660-670

  Michielin, Olivier ^a,b   Hoeller, Christoph ^c,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c Universitatsklinik fur Dermatologie   (Austria)

^d Division of General Dermatology   (Austria)

Author keywords

Chemotherapy; Combination; Europe; Immunotherapy; Ipilimumab; Melanoma; Targeted therapy

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; B RAF KINASE INHIBITOR; BINIMETINIB; BMS 936559; CANCER VACCINE; COBIMETINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; DASATINIB; ENCORAFENIB; FOTEMUSTINE; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; LIRILUMAB; MPDL 3280A; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; STEM CELL FACTOR; SUNITINIB; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB; B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ACNE; ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; LONG TERM SURVIVAL; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PHOTOTOXICITY; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLASSIFICATION; DISEASE COURSE; DRUG THERAPY; FORECASTING; PATHOLOGY; PROCEDURES; PROGNOSIS; TRENDS;

ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; DISEASE PROGRESSION; DRUG THERAPY; FORECASTING; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84941023024     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.05.012     Document Type: Review

References (156)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Garbe C., Eigentler T.K., Keilholz U., Hauschild A., Kirkwood J.M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011, 16:5-24.
4. Eggermont A.M., Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011, 47:2150-2157.
5. Garbe C., Terheyden P., Keilholz U., Kölbl O., Hauschild A. Treatment of melanoma. Dtsch Arztebl Int 2008, 105:845-851.
6. Mekinist (trametinib) Summary of Product Characteristics, August 2014. Available at: . http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002643/WC500169657.pdf.
7. KEYTRUDA® (pembrolizumab) US Prescribing Information. Available at: . http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf.
8. Ono Pharmaceutical Co., Ltd. Press release 4 July 2014. Available at: . http://www.ono.co.jp/eng/news/pdf/sm_cn140704.pdf%20[last%20accessed%20December%202014].
9. Ribas A., Hersey P., Middleton M.R., Gogas H., Flaherty K.T., Sondak V.K., et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012, 18:336-341.
10. Dummer R., Guggenheim M., Arnold A.W., Braun R., von Moos R. Project Group Melanoma of the Swiss Group for Clinical Cancer Research. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2011, 141:w13320.
11. Dummer R., Hauschild A., Guggenheim M., Keilholz U., Pentheroudakis G. ESMO Guidelines Working Group. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii86-vii91.
12. Garbe C., Peris K., Hauschild A., Saiag P., Middleton M., Spatz A., et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2012. Eur J Cancer 2012, 48:2375-2390.
13. NCCN clinical practice guidelines in oncology: melanoma. Version 12.2015, December 2014. Available at: . http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf.
14. Plugfelder A., Kochs C., Blum A., Capellaro M., Czeschik C., Dettenborn T., et al. S3-guideline "diagnosis, therapy and follow-up of melanoma" - short version. J Dtsch Dermatol Ges 2013, 11:563-602.
15. Dummer R., Hauschild A., Guggenheim M., Jost L., Pentheroudakis G. ESMO Guidelines Working Group. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v194-v197.
16. Serrone L., Zeuli M., Sega F.M., Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000, 19:21-34.
17. McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer R., et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
18. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
19. Chapman P.B., Einhorn L.H., Meyers M.L., Saxman S., Destro A.N., Panageas K.S., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
20. Hamm C., Verma S., Petrella T., Bak K., Charette M. Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 2008, 34:145-156.
21. Ives N.J., Stowe R.L., Lorigan P., Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 2007, 25:5426-5434.
22. Middleton M.R., Grob J.J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158-166.
23. Agarwala S.S., Kirkwood J.M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000, 5:144-151.
24. Quéreux G., Dréno B. Fotemustine for the treatment of melanoma. Expert Opin Pharmacother 2011, 12:2891-2904.
25. Hersh E., Del Vecchio M., Brown M., Kefford R., Loquai C., Testori A., et al. Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM). Pigment Cell Melanoma Res 2012, 25:836-903.
26. Cheng S., Chu P., Hinshaw M., Smith K., Maize J., Sferruzza A. Frequency of mutations associated with targeted therapy in malignant melanoma patients. J Clin Oncol 2011, 29(Suppl.). abstract 8597.
27. Colombino M., Capone M., Maio M., De Giorgi V., Cossu A., Lissia A., et al. Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients. J Clin Oncol 2011, 29(Suppl.). abstract 8574.
28. Pratilas C.A., Solit D.B. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010, 16:3329-3334.
29. Long G.V., Menzies A.M., Nagrial A.M., Haydu L.E., Hamilton A.L., Mann G.J., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-1246.
30. Cantwell-Dorris E.R., O'Leary J.J., Sheils O.M. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011, 10:385-394.
31. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
32. Carnahan J., Beltran P.J., Babij C., Le Q., Rose M.J., Vonderfecht S., et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 2010, 9:2399-2410.
33. Zelboraf (vemurafenib) Summary of Product Characteristics, December 2013. Available at: . http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf.
34. Larkin J.M.G., Del Vecchio M., Ascierto P.A., Schachter J., Garbe C., Neyns B., et al. Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma. J Clin Oncol 2013, 31(Suppl.). abstract 9046.
35. Dummer R., Goldinger S.M., Turtschi C.P., Eggmann N.B., Michielin O., Mitchell L., et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014, 50:611-621.
36. Kefford R.F., Maio M., Arance A., Nathan P., Blank C., Avril M.F., et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. Pigment Cell Melanoma Res 2013, 26:965.
37. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
38. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
39. Dummer R., Rinderknecht J., Goldinger S.M. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012, 366:480-481.
40. Fisher R., Larkin J. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res 2012, 4:243-252.
41. Hauschild A., Grobb J., Demidov L., Jouary T., Gutzmer R., Millward M., et al. An update on overall survival (OS) and follow-on therapies in BREAK-3. Ann Oncol 2014, 25(Suppl. 4):iv374-iv393.
42. Long G.V., Trefzer U., Davies M.A., Kefford R.F., Ascierto P.A., Chapman P.B., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
43. Tafinlar (dabrafenib) Summary of Product Characteristics, September 2013. Available at: . http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002604/WC500149671.pdf.
44. Stuart D.D., Li N., Poon D.J., Aardalen K., Kaufman S., Merritt H., et al. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor. Cancer Res 2012, 72(Suppl. 1). abstract 3790.
45. Dummer R., Robert C., Nyakas M., McArthur G.A., Kudchadkar R.R., Gomez-Roca C., et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. J Clin Oncol 2013, 31(Suppl.). abstract 9028.
46. Shi H., Hugo W., Kong X., Hong A., Koya R.C., Moriceau G., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discovery 2014, 4:80-93.
47. Wagle N., Emery C., Berger M.F., Davis M.J., Sawyer A., Pochanard P., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011, 29:3085-3096.
48. Chan M., Haydu L., Menzies A.M., Azer M.W.F., Klein O., Guminski A., et al. Clinical characteristics and survival of BRAF-mutant. J Clin Oncol 2013, 31(Suppl.). abstract 9062.
49. Kim K.B., Flaherty K.T., Chapman P.B., Sosman J.A., Ribas A., McArthur G.A., et al. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol 2011, 29(Suppl.). abstract 8519.
50. Kim K.B., Kefford R., Pavlick A.C., Infante J.R., Ribas A., Sosman J.A., et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013, 31:482-489.
51. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-214.
52. Ascierto P.A., Schadendorf D., Berking C., Agarwala S.S., van Herpen C.M., Queirolo P., et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256.
53. Carvajal R.D., Sosman J.A., Quevedo F., Milhem M.M., Joshua A.M., Kudchadkar R.R., et al. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J Clin Oncol 2013, 31(Suppl.). abstract CRA9003.
54. Flaherty K., Arenberger P., Ascierto P.A., De Groot J.W., Hallmeyer S., Long G.V., et al. NEMO: a phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma. J Clin Oncol 2014, 32(Suppl. 5s). abstract TPS9102.
55. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
56. Thakur M., Fisher R., Salangsang F., Landman A., Sellers W., Pryer N., et al. Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Cancer Res 2013, 73. abstract LB-144.
57. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014, 371:1877-1888.
58. Robert C., Karaszewska B., Schachter J., Rutkowski P., Mackiewicz A., Stroiakovski D., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015, 372:30-39.
59. Mekinist (trametinib) Highlights of Prescribing Information, January 2014. Available at: . http://us.gsk.com/products/assets/us_mekinist.pdf.
60. Tafinlar (dabrafenib) Highlights of Prescribing Information, January 2014. Available at: . http://us.gsk.com/products/assets/us_tafinlar.pdf.
61. Johnson D.B., Flaherty K.T., Weber J.S., Infante J.R., Kim K.B., Kefford R.F., et al. Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014, 32:3697-3704.
62. Cebon J.S., Flaherty K., Weber J.S., Kim K., Infante J.R., Daud A., et al. Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). J Clin Oncol 2013, 31(Suppl.). abstract 9016.
63. Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014, 371(20):1867-1876.
64. Kefford R., Miller W.H., Tan D.S.-W., Sullivan R.J., Long G., Dienstmann R., et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral. J Clin Oncol 2013, 31(1):9029.
65. Fedorenko I.V., Gibney G.T., Sondak V.K., Smalley K.S. Beyond BRAF: where next for melanoma therapy?. Br J Cancer 2015, 112(2):217-226.
66. Shtivelman E., Davies M.Q., Hwu P., Yang J., Lotem M., Oren M., et al. Pathways and therapeutic targets in melanoma. Oncotarget 2014, 5(7):1701-1752.
67. Arkenau H.T., Kefford R., Long G.V. Targeting BRAF for patients with melanoma. Br J Cancer 2011, 104(3):392-398.
68. Smalley K.S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010, 130:28-37.
69. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
70. Omholt K., Grafström E., Kanter-Lewensohn L., Hansson J., Ragnarsson-Olding B.K. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011, 17:3933-3942.
71. Guo J., Si L., Flaherty K.T., Xu X., Zhu Y., Corless C.L., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harbouring c-Kit mutation or amplification. J Clin Oncol 2011, 29:2904-2909.
72. Carvajal R.D., Antonescu C.R., Wolchok J.D., Chapman P.B., Roman R.A., Teitcher J., et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305:2327-2334.
73. Bastian B.C., Esteve-Puig R. Targeting activating KIT signaling for melanoma therapy. J Clin Oncol 2013, 31:3288-3290.
74. Carvajal R., Lawrence D., Weber J.S., Gajewski T.F., Gonzalez R., Lutzky J., et al. LBA5_PR - phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). Ann Oncol 2014, 25(Suppl. 4):iv374-iv393.
75. Finn L., Markovic S.N., Joseph R.W. Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012, 10:23.
76. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol 2012, 23(Suppl. 8):viii10-viii14.
77. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
78. Bernatchez C., Radvanyi L.G., Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 2012, 39:215-226.
79. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
80. Rosenberg S.A. Raising the bar the curative potential of human cancer immunotherapy. Sci Transl Med 2012, 4:127ps8.
81. Finn O.J. Cancer immunology. N Engl J Med 2008, 358:2704-2715.
82. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
83. Kirkwood J.M., Tarhini A.A., Panelli M.C., Moschos S.J., Zarour H.M., Butterfield L.H.L. Next generation of immunotherapy for melanoma. J Clin Oncol 2008, 26:3445-3455.
84. Fang L., Lonsdorf A.S., Hwang S.T. Immunotherapy for advanced melanoma. J Invest Dermatol 2008, 128:2596-2605.
85. Fong L., Small E.J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008, 26:5275-5283.
86. Zigler M., Villares G.J., Lev D.C., Melnikova V.O., Bar-Eli M. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol 2008, 9:307-311.
87. Korman A.J., Peggs K.S., Allison J.P. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006, 90:297-339.
88. Schneider H., Downey J., Smith A., Zinselmeyer B.H., Rush C., Brewer J.M., et al. Reversal of the TCR stop signal by CTLA-4. Science 2006, 313:1972-1975.
89. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
90. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
91. Dummer R., Schadendorf D., Ascierto P.A., Larkin J., Lebbé C., Hauschild A. Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials. J Transl Med 2014, 12(Suppl. 1):P8.
92. Patt D.A., Rembert D., Bhor M., Bhowmik D., Rao S.A. A real-world observational study of patients with advanced melanoma receiving first-line ipilimumab in a community practice setting. J Cancer Therapy 2014, 5:1049-1058.
93. Margolin K.A., Wong S.L., Penrod J.R., Song J., Chang I.-F., Johnson D.B., et al. Effectiveness and safety of first-line ipilimumab for advanced melanoma: a U.S. multisite retrospective chart review. Pigment Cell Melanoma Res 2013, 26:986.
94. Pennock G.K., Waterfield W., Wolchok J.D. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?. Am J Clin Oncol 2011, 35:606-611.
95. Ribas A., Chmielowski B., Glaspy J.A. Do we need a different set of response assessment criteria for tumor immunotherapy?. Clin Cancer Res 2009, 15:7116-7118.
96. Hamid O., Schmidt H., Nissan A., Ridolfi L., Aamdal S., Hansson J., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011, 9:204.
97. Wolchok J.D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
98. Ascierto P.A., Simeone E., Giannarelli D., Grimaldi A.M., Romano A., Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012, 10:107.
99. Di Giacomo A.M., Danielli R., Calabrò L., Bertocci E., Nannicini C., Giannarelli D., et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011, 60:467-477.
100. Weber J.S. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007, 12:864-872.
101. Lebbé C., Weber J.S., Maio M., Neyns B., Harmankaya K., Hamid O., et al. Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. J Clin Oncol 2013, 31(Suppl.). abstract 9053.
102. Maio M., Bodarenko I., Robert C., Thomas L., Garbe C., Testori A., et al. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. Eur J Cancer 2013, 49(Suppl. 2). abstract 3704.
103. Prieto P.A., Yang J.C., Sherry R.M., Hughes M.S., Kammula U.S., White D.E., et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012, 18:2039-2047.
104. Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur J Cancer 2013, 49(Suppl. 2). abstract 24LBA.
105. Bedikian A.Y., Johnson M.M., Warneke C.L., Papadopoulos N.E., Kim K., Hwu W.J., et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008, 26:624-633.
106. Danielli R., Ridolfi R., Chiarion-Sileni V., Queirolo P., Testori A., Plummer R., et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother 2012, 61:41-48.
107. Del Vecchio M., Di Guardo L., Ascierto P.A., Grimaldi A.M., Sileni V.C., Pigozzo J., et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014, 50:121-127.
108. Khan S.A., Callahan M., Postow M.A., Chapman P.B., Schwartz G.K., Dickson M.A., et al. Ipilimumab in the treatment of uveal melanoma: the Memorial Sloan-Kettering Cancer Center experience. J Clin Oncol 2012, 30(Suppl.). abstract 8549.
109. Khattak M.A., Fisher R., Hughes P., Gore M., Larkin J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res 2013, 23:79-81.
110. Maio M., Danielli R., Chiarion-Sileni V., Pigozzo J., Parmiani G., Ridolfi R., et al. Efficacy and safety of ipilimumab in patients with pretreated, uveal melanoma. Ann Oncol 2013, 24:2911-2915.
111. Mangana J., Goldinger S.M., Schindler K., Rozati S., Frauchiger A.L., Rechsteiner M., et al. Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival?. J Clin Oncol 2013, 31(Suppl.). abstract 9025.
112. Shahabi V., Whitney G., Hamid O., Schmidt H., Chasalow S.D., Alaparthy S., et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:733-737.
113. Zimmer L., Eigentler T.K., Vaubel J.-M., Mohr P., Jradi Z., Kiecker F., et al. Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups. J Clin Oncol 2014, 32(Suppl. 5s). abstract 9031.
114. Kelderman S., Heemskerk B., van Tinteren H., van den Brom R.R., Hospers G.A., van den Eertwegh A.J., et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014, 63:449-458.
115. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014, 371(23):2189-2199.
116. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
117. Hoos A., Ibrahim R., Korman A., Abdallah K., Berman D., Shahabi V., et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010, 37:533-546.
118. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30:2046-2054.
119. Weber J., Thompson J.A., Hamid O., Minor D., Amin A., Ron I., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15:5591-5598.
120. O'Day S.J., Maio M., Chiarion-Sileni V., Gajewski T.F., Pehamberger H., Bondarenko I.N., et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010, 21:1712-1717.
121. YERVOY (ipilimumab) Summary of Product Characteristics, December 2013. Avaliable at: . http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf.
122. Kaehler K.C., Piel S., Livingstone E., Schilling B., Hauschild A., Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010, 37:485-498.
123. Weber J.S., Kahler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30:2691-2697.
124. Postow M.A., Callahan M.K., Wolchok J.K. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015, 1-2. [Epub ahead of print].
125. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
126. Blank C.U. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol 2014, 26:204-214.
127. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
128. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
129. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
130. Ribas A, Pzanov I, Dummer R, Daud A, Schadendorf D, Robert C, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory (IPI-R) melanoma (MEL). Late breaking abstract presented at the 11th International Congress of the Society for Melanoma Research, 13-16 November 2014, Zurich, Switzerland.
131. Robert C., Joshua A.M., Weber J.S., Ribas A., Hodi F.S., Kefford R.F., et al. Pembrolizumab (PEMBRO; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules. Ann Oncol 2014, 25(Suppl. 5):v1-v41.
132. Hodi F.S., Kluger H.M., Sznol M., Carvajal R.D., Lawrence D.P., Atkins M.B., et al. Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in a phase 1 trial. Pigment Cell Melanoma Res 2014, 27:1169-1241.
133. Weber J.S., Minor D.R., D'Angelo S.P., Hodi F.S., Gutzmer R., Neyns B., et al. A phase 3 open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) vs investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy (CheckMate 037). Ann Oncol 2014, 25(Suppl. 5):v1-v41.
134. D'Angelo SP, Larkin J, Weber J, Hodi FS, Gutzmer R, Neyns B, et al. Efficacy and safety of nivolumab vs investigator's choice chemotherapy (ICC) in subgroups of patients with advanced melanoma after prior anti-CTLA-4 therapy. Late breaking abstract presented at the 11th International Congress of the Society for Melanoma Research, 13-16 November 2014, Zurich, Switzerland.
135. Tykodi S.S., Brahmer J.R., Hwu W.-J., Chow L.Q., Topalian S.L., Hwu P., et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy. J Clin Oncol 2013, 31(Suppl.). abstract 2510.
136. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
137. Hamid O., Sosman J.A., Lawrence D.P., Sullivan R.J., Ibrahim N., Kluger H.M., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 2013, 31(Suppl.). abstract 9010.
138. Kaufman H.L., Andtbacka R.H.I., Collichio F.A., Amatruda T., Senzer N.N., Chesney J., et al. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2014, 32(Suppl. 5s). abstract 9008a.
139. Chiarion-Sileni V., Pigozzo J., Ascierto P.A., Maio M., Danielli R., Del Vecchio M., et al. Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP). J Clin Oncol 2013, 31(Suppl.). abstract 9548.
140. Dummer R, Larkin J, Lebbe C, Schadendorf D, Hanaan J. Exploratory 12-week survival analysis of patients with unresectable or metastatic melanoma treated with ipilimumab in a phase 3 trial (MDX010-20). 2012 Presented at 8th EADO Congress 2012: poster presentation P51.
141. Ackerman A., McDermott D.F., Lawrence D.P., Gunturi A., Flaherty K.T., Giobbie-Hurder A., et al. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. J Clin Oncol 2012, 30(Suppl.). abstract 8569.
142. Ascierto P.A., Simeone E., Grimaldi A.M., Curvietto M., Esposito A., Palmieri G., et al. Do BRAF inhibitors select for populations with different disease progression kinetics?. J Transl Med 2013, 11:61.
143. Ascierto P.A., Simeone E., Chiarion-Sileni V., Queirolo P., Del Vecchio M., Di Guardo L., et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of ipilimumab expanded access programme (EAP). J Clin Oncol 2013, 31(Suppl.). abstract 9035.
144. Di Giacomo A.M., Calabrò L., Danielli R., Fonsatti E., Bertocci E., Pesce I., et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013, 62:1021-1028.
145. Wang W., Yu D., Sarnaik A.A., Yu B., Hall M., Morelli D., et al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med 2012, 10:146.
146. Jure-Kunkel M., Selby M., Lewis K., Masters G., Valle J., Grosso J., et al. Nonclinical evaluation of the combination of mouse IL-21 and anti-mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models. J Clin Oncol 2013, 31(Suppl.). abstract 3019.
147. Kudchadkar R.R., Gibney G.T., Dorman D., Merek S., Ramadan H., Chen A., et al. A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma. J Clin Oncol 2014, 32(Suppl. 5s). abstract 9098.
148. Puzanov I., Milhem M.M., Andtbacka R.H.I., Minor D.R., Hamid O., Li A., et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 2014, 32(Suppl. 5). abstract 9029.
149. Gibney G.T., Hamid O., Gangadhar T.C., Lutzky J., Olszanski A.J., Gajewski T., et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol 2014, 32(Suppl. 5). abstract 3010.
150. Hodi F.S., Lee S., McDermott D.F., Rao U.N., Butterfield L.H., Tarhini A.A., et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014, 312:1744-1753.
151. Kluger H.M., Sznol M., Callahan M.K., Postow M.A., Gordon R.A., Segal N.H., et al. Survival, response duration, and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL). Pigment Cell Melanoma Res 2014, 27:1169-1241.
152. Kluger H., Sznol M., Callahan M., Postow M., Gordon R., Segal N.H., et al. Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). Ann Oncol 2014, 25(Suppl. 4):iv374-iv393.
153. Wolchok J.D., Kluger H.M., Callahan M.K., Postow M.A., Gordon R.A., Segal N.H., et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). J Clin Oncol 2013, 31(Suppl.). abstract 9012.
154. Rizvi N.A., Infante J.R., Gibney G.T., Bertino E.M., Cooley S.A., Lekatis K., et al. A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors. J Clin Oncol 2013, 31(Suppl.). abstract TPS3106.
155. Sanborn R.E., Sharfman W.H., Segal N.H., Hodi F.S., Wolchok J.D., Urba W.J., et al. A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. J Clin Oncol 2013, 31(Suppl.). abstract TPS3110.
156. Ribas A., Hodi F.S., Callahan M., Konto C., Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013, 368:1365-1366.